Payer / HTA meeting · Dr. Gabriel Yamamoto

07 Jul 2026 · In person · Dr. Gabriel Yamamoto, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0138—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Steroid-sparing strategies
APRIL pathway mechanism
Treatment burden and fatigue

Scientific content used

NPH mechanism-of-action deck
Surrogate-endpoint evidence review

Questions raised

Is there any data on APRIL inhibition in FSGS?
What is the immunoglobulin monitoring recommendation?

Notes

Payer / HTA meeting with academic nephrologist at Christie NHS Foundation Trust. Discussed steroid-sparing strategies, april pathway mechanism, treatment burden and fatigue.

Insights captured (1)

Capture insight

INS-0043Medium
Steroid-sparing strategies
Steroid-sparing strategies: gap in current materials reported by academic nephrologist (GB).
Outcome recorded

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0138

Audit history (0)

All create, update and approval events for this record

No audit events in sample data